title: The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex.
abstract: G protein-coupled receptors (GPCRs) mediate the majority of physiologic responses to hormones and neurotransmitters. However, many GPCRs exhibit varying degrees of agonist-independent G protein activation. This phenomenon is referred to as basal or constitutive activity. For many of these GPCRs, drugs classified as inverse agonists can suppress basal activity. There is a growing body of evidence that basal activity is physiologically relevant, and the ability of a drug to inhibit basal activity may influence its therapeutic properties. However, the molecular mechanism for basal activation and inhibition of basal activity by inverse agonists is poorly understood and difficult to study, because the basally active state is short-lived and represents a minor fraction of receptor conformations. Here, we investigate basal activation of the G protein Gs by the beta(2) adrenergic receptor (beta(2)AR) by using purified receptor reconstituted into recombinant HDL particles with a stoichiometric excess of Gs. The beta(2)AR is site-specifically labeled with a small, environmentally sensitive fluorophore enabling direct monitoring of agonist- and Gs-induced conformational changes. In the absence of an agonist, the beta(2)AR and Gs can be trapped in a complex by enzymatic depletion of guanine nucleotides. Formation of the complex is enhanced by the agonist isoproterenol, and it rapidly dissociates on exposure to concentrations of GTP and GDP found in the cytoplasm. The inverse agonist ICI prevents formation of the beta(2)AR-Gs complex, but has little effect on preformed complexes. These results provide insights into G protein-induced conformational changes in the beta(2)AR and the structural basis for ligand efficacy.
authors.affiliation: Department of Molecular and Cellular Physiology, Stanford University Medical School, Stanford, CA 94305, USA.
authors.forename: Xiao Jie
authors.initials: XJ
authors.lastname: Yao
authors.forename: Gisselle
authors.initials: G
authors.lastname: Vélez Ruiz
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Whorton
authors.forename: Søren G F
authors.initials: SG
authors.lastname: Rasmussen
authors.forename: Brian T
authors.initials: BT
authors.lastname: DeVree
authors.forename: Xavier
authors.initials: X
authors.lastname: Deupi
authors.forename: Roger K
authors.initials: RK
authors.lastname: Sunahara
authors.forename: Brian
authors.initials: B
authors.lastname: Kobilka
mesh_terms: D058672:Adrenergic beta-2 Receptor Antagonists; D001643:Bridged Bicyclo Compounds; D019204:GTP-Binding Proteins / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D055550:Protein Stability; D018343:Receptors, Adrenergic, beta-2 / Q000737:chemistry / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D058672:Adrenergic beta-2 Receptor Antagonists; D001643:Bridged Bicyclo Compounds; D008024:Ligands; D018343:Receptors, Adrenergic, beta-2; D019204:GTP-Binding Proteins; C028381:monobromobimane